IUPAC name:
6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
CAS No.
1744-22-5
Molecular Weight:
234.20g.mol−1
Molecular Formula:
C8H5F3N2OS
Granule:
The mode of action is unknown; it’s believe that it has inhibitory effect on glutamate release (activation of glutamate reuptake), and inactivity effect on voltage-dependent sodium channels, and also ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors.
Riluzole is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS).
Oncology
Cas No: 857890-39-2
Mechanism Of Action: Lenvatinib is classified as a receptor tyrosine kinase (RTK) inhibitor that effectively suppresses the kinase activities of vascular endothelial growth factor (VEGF)
Oncology
Cas No: 1187431-43-1
Mechanism Of Action: Trametinib is identified as a reversible and remarkably selective allosteric inhibitor of MEK1 and MEK2. Through its high-affinity binding to unphosphorylated MEK1
Oncology
Cas No: 1195768-06-9
Mechanism Of Action: Dabrafenib is recognized as a competitive and highly selective inhibitor of BRAF. Its mechanism of action involves binding to the ATP pocket
Oncology
Cas No: 1231929-97-7
Mechanism Of Action: Abemaciclib demonstrates high selectivity in inhibiting CDK4 and CDK6 with potent activity in the low nanomolar range. By inhibiting the phosphorylation of
Cardiovascular
Cas No: 936623-90-4
Mechanism Of Action: Sacubitril/valsartan is a medication that exerts its effects through the dual inhibition of neprilysin, an enzyme responsible for degrading certain peptides, and
Anti-Anemic
Cas No: 808118-40-3
Mechanism Of Action: Anemia is a common complication of chronic kidney disease that can be caused by reduced production of renal erythropoietin (EPO), functional iron
